Next Article in Journal
Lineage Replacement Associated with Fitness Gain in Mammalian Cells and Aedes aegypti: A Catalyst for Dengue Virus Type 2 Transmission
Previous Article in Journal
Antimicrobial Effects of L-Chg10-Teixobactin against Enterococcus faecalis In Vitro
Previous Article in Special Issue
Periodontal Pathogens Inhabit Root Caries Lesions Extending beyond the Gingival Margin: A Next-Generation Sequencing Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Molecular Detection of Streptococcus downii sp. nov. from Dental Plaque Samples from Patients with Down Syndrome and Non-Syndromic Individuals

by
Eliane García-Mato
1,
Lucía Martínez-Lamas
2,
Maximiliano Álvarez-Fernández
2,
Iván Varela-Aneiros
1,
Marcio Diniz-Freitas
1,*,
Jacobo Limeres-Posse
1 and
Pedro Diz-Dios
1,*
1
Medical-Surgical Dentistry Research Group (OMEQUI), Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela (USC), 15705 Santiago de Compostela, Spain
2
Clinical Microbiology, Microbiology and Infectiology Group, Galicia Sur Health Research Institute, Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo, 36312 Vigo, Spain
*
Authors to whom correspondence should be addressed.
Microorganisms 2022, 10(6), 1098; https://doi.org/10.3390/microorganisms10061098
Submission received: 17 April 2022 / Revised: 12 May 2022 / Accepted: 23 May 2022 / Published: 26 May 2022
(This article belongs to the Special Issue Oral Microbiota and Associated Local and Focal Infections)

Abstract: Background

A new bacterial species has recently been identified in the dental plaque of an adolescent with Down syndrome. The species is known as Streptococcus downii sp. nov. (abbreviated to S. downii), and it inhibits the growth of S. mutans and certain periodontal pathogens. The aim of this study was to determine the distribution of S. downii in the oral cavity of individuals with Down syndrome. Methods: A specific polymerase chain reaction for the operon of bacteriocin (class IIb lactobin A/cerein 7B family) was designed to detect S. downii in individuals with Down syndrome (n = 200) and in the general population (n = 100). We also compared the whole genome of S. downii and the regions related to its bacteriocins against 127 metagenomes of supragingival plaque of the “Human Microbiome Project”. Results: We detected the specific gene of the S. downii bacteriocin in an individual with Down syndrome (Cq, 34.52; GE/μL, 13.0) and in an individual of the non-syndromic control group (Cq, 34.78 Cq; GE/μL, 4.93). The prevalence of S. downii was ≤1% both in Down syndrome and in the general population, which did not allow for clinical-microbiological correlations to be established. This result was confirmed by detecting only one metagenome with an ANIm with approximately 95% homology and with 100% homology with ORFs that code class IIb lactobiocin A/cerein 7B bacteriocins among the 127 metagenomes of the “Human Microbiome Project” tested. Conclusions: The detection rate of S. downii in the supragingival dental plaque was very low, both in the Down syndrome individuals and in the non-syndromic controls. A clinical-microbiological correlation could therefore not be established.

1. Introduction

Dental caries is the most prevalent non-transmittable disease globally, given the estimated 2.3 billion individuals with caries in their permanent teeth and more than 530 million children with caries in their temporary teeth [1]. Although genetic, microbial, immunological, behavioral and environmental factors are involved in the development of caries, massive sequencing techniques have helped establish that caries is an expression of dysbiosis of the oral microbiome [2]. However, it has classically been considered that the fundamental etiological agent is a complex polymicrobial community in which Streptococcus mutans has an especially relevant role [3]. Paradoxically, a number of bacterial species have been identified that inhibit the growth of S. mutans, and participate in the homeostasis of the oral biofilm and consequently exhibit anticaries potential. These species include certain hydrogen peroxide-producing streptococci such as S. oligofermentans [4] and S. A12 [5]; arginolytic streptococci such as S. gordonii, S. sanguinis, S. parasanguinis, S. australis and S. cristatus [6]; bacteriocin-producing streptococci; bacteriocin-like inhibitory substances such as S. salivarius [7]; and streptococci that combine several of these mechanisms of action such as S. oralis subsp. dentisani (abbreviated to S. dentisani), which produce bacteriocin and have arginolytic activity [8,9].
Down syndrome (DS) is the most common chromosomal anomaly, with an estimated prevalence of one case for every 800 live births [10]. This chromosomal disorder is characterized by a varying degree of intellectual disability and numerous systemic disorders including cardiac, hematological, and endocrine abnormalities [10]. The most relevant oral manifestations of DS are macroglossia, malocclusions, delayed tooth eruption and periodontal disease [11]. It has been suggested that the incidence of dental caries in children and adolescents with DS is lower than in the non-syndromic population [12,13,14,15], although the quality of the available evidence does not allow for a definitive inference [16]. Based on this argument, the Special Care Dentistry Unit of the University of Santiago de Compostela (Spain) analyzed the oral flora of a patient group with DS with no evidence of caries to search for bacterial strains with antagonistic effects against S. mutans, which helped identify a new bacterial species called Streptococcus downii sp. nov. (abbreviated to S. downii) [17].
S. downii is a bacteria of the Streptococcus genus whose genetic and taxonomic analysis places it within the oral group, the Streptococcaceae family and the Lactobacillales order. S. downii is an alpha-hemolytic, Gram-positive coccus that differs biochemically from the closely related Streptococcus species due to the production of α-galactosidase, β-galactosidase and N-acetyl-β-D-glucosaminidase, and by the absence of arginine dihydrolasedesiminase and IgA1 protease. The most attractive characteristic of S. downii due to its potential for preserving oral health is that it inhibits the growth of S. mutans and certain periodontal pathogens such as Aggregatibacter actinomycetemcomitans, both in plaque growth [17] and in an in vitro biofilm model [18]. Although its mechanism of action has not been definitively clarified, the genomic analysis of S. downii has revealed the presence of putative genes of the family of bacteriocin IIb lactobinA/cerein 7B (data not shown).
The aim of this study was to determine the distribution of S. downii in the oral cavity of individuals with DS and in the general population and to investigate whether there is a clinical-microbiological correlation in terms of the prevalence of caries and periodontal disease.

2. Materials and Methods

2.1. Design of a Specific PCR for the Bacteriocin Operon

In the S. downii MZNX00000000.1 sequence, we selected the contig that contained the sequence corresponding to the bacteriocin. We designed specific primers for the bacteriocin operon (class IIb lactobin A/cerein 7B family) with the Primer-BLAST program (https://www.ncbi.nlm.nih.gov/tools/primer-blast/ (accessed on 10 June 2017). The sequences of the starters were as follows: S. downii-FORWARD CAAAGTGTAGCAGATGTGGTCAGAAC and S. downii-REVERSE CTTTTCTTCTCACTTATCCATTCGC (Figure 1).
Through partial magnification of the gene rRNA 16S, we performed a specificity assay on DNA from seven bacterial species related to S. downii (S. mitis, S. salivarius, S. dentisani 8313, S. dentisani 8312, S. mutans, S. sobrinus and S. sanguinis DSTIZ 20567), including an internal reaction control. We showed that the designed primers were specific for S. downii and amplified a region included in the bacteriocin operon of 271 bp (Figure 2a).
With a fixed quantity of bacterial DNA (1 ng), we performed serial dilutions of the S. downii DNA (dilution factor range: 5–390,625). The lower limit of detection was approximately 1.63 pg, which corresponded to 736 genomic equivalents (GEs) of S. downii DNA (Figure 2b).

2.2. Validation of the Specific PCR

To validate the quantitative PCR using specific Taqman probes for detecting and quantifying a region of the gene of bacterial RNA 16S and of a sequence adjacent to a bacteriocin gene of S. downii, we analyzed four samples of supragingival dental plaque seeded with S. downii at 3000 colony-forming units (CFU)/mL. To process the samples, we first centrifuged them at 13,000 rpm for 15 min. We used 250 μL for the resuspension of the bacteria and the DNA extraction using the QIAamp DNA Blood Mini Kit (Qiagen, Germany). The column’s elution volume was 100 μL; the DNA concentration was therefore 30 GEs of S. downii per μL. The amplification was performed in real time using a duplicate for each sample. To perform the assay, we used 2 μL per sample. To proceed with the quantification, we included a curve of the DNA pattern for S. downii obtained with the same purification kit. The curve included six determinations corresponding to serial dilutions at 1/5 starting at 92,000 GEs and ending at 29 GEs.
Table S1 shows the mean quantification cycle (Cq) values and the mean concentrations obtained for the target (bacteriocin) and control genes (16S rRNA) estimated based on the pattern curve obtained by diluting the bacterial DNA of S. downii quantified by fluorometry. The detected GEs of S. downii were similar to the CFUs seeded in the samples, with a mean concentration of 24 GE/μL.

2.3. Study Population

We designed an observational, cross-sectional, case-control study that was approved by the Research Ethics Committee of Santiago-Lugo, Spain (registration code: 2018/510). We established a convenience group of cases consisting of 200 white male individuals with DS recruited consecutively from the attendees of educational and occupational therapy centers of Galicia (Spain) from 2018 to 2019. For the recruitment and to facilitate the collaboration of the individuals with DS in a known setting, the researchers travelled to the centers of A Coruña, Lugo, Pontevedra, Ferrol, Ourense, Vigo and Santiago de Compostela.
The applied inclusion criteria were as follows: confirmed genetic diagnosis of DS, age >3 years (coinciding with the age of complete eruption of the temporary dentition), presence in the mouth of Ramfjord teeth [19] or of their adjacent teeth (of the corresponding temporary teeth, if applicable), sufficient collaboration to allow for intraoral examination and sampling and voluntary participation in the study (informed consent signed by the participants or their legal representatives). We excluded individuals with chronic disease, medication consumption and previous procedures (e.g., radiation therapy of the head and neck) that reduced salivary flow, and we excluded those who were administered antibiotics in the previous 3 months or who regularly used antiseptic mouthwash in the previous week.
Applying the same criteria, we established a control group (CG) consisting of 100 non-syndromic individuals among the companions of the patients with DS.

2.4. Oral Health Condition and Collection of Samples

Each participant’s age was recorded, and their oral health state was assessed. Due to the potential limitations in some of the patients’ collaboration, the duration of the examination was minimized by limiting it to the six Ramfjord teeth [19]. The following clinical variables were recorded: index of visible dental plaque around the tooth [20]; presence of active caries applying the International Caries Detection and Assessment System [21]; gingivitis, when the probing depth was <4 mm and bleeding on probing detected in more than two locations [22]; and periodontitis, when the probing depth was ≥4 mm in at least one location [23].
In total, two samples of supragingival dental plaque were collected from each patient using a conventional metal curette (Hu-friedy, Frankfurt, Germany). The curette was inserted into an Eppendorf tube containing 50 μL of saline solution and transported to the laboratory, where it was stored at −20 °C until processing. The samples were unfrozen at room temperature and transferred to a 2-mL tube. The process of centrifugation and DNA extraction was then started, as described in Section 2.2. In all of the sample processing series for the DS group and CG, we included two samples of positive controls contaminated with S. downii at 3000 CFU/mL.

2.5. Detection of S. downii in Metagenomes of Supragingival Plaque of the “Human Microbiome Project”

To evaluate the prevalence of S. downii in the supragingival plaque of healthy individuals, we compared the whole genome and the regions related to S. downii bacteriocins against metagenomes of supragingival plaque of the Human Microbiome Project [24]. Of the 217 metagenomes initially identified, we selected 127 that were assembled, generated by whole genome sequencing (WSG) techniques. We calculated the average nucleotide identity based on MUMmer (ANIm) between the S. downii genome and each of the selected metagenomes, applying the NUCmer tool [25] using pyANI (v0.2.7) [26], as previously described [27]. To confirm the presence of orthologous genes related to bacteriocins, we used the Blast reciprocal best hits (BRBH) method [28].

3. Results and Discussion

3.1. Prevalence of S. downii in the Oral Cavity of Individuals with Down Syndrome and of the General Population

Bacterial DNA was detected in all of the analyzed samples from the DS group and CG. The range of the bacterial 16S rRNA was 12.15–24.90 Cqand 4.29 × 103–8.90 × 106 GE/μL. We detected the specific gene of the S. downii bacteriocin in an individual with DS (prevalence of 0.5%), with values of 34.52 Cq and 13.0 GE/μL. We also detected the specific gene of the S. downii bacteriocin in an individual in the CG (prevalence of 1%), with values of 34.78 Cq and 4.93 GE/μL. In all of the positive contaminated control samples, we identified the specific gene of the S. downii bacteriocin.
Bacteriocins are small peptides or proteins of bacterial origin that inhibit the growth of other bacteria, favoring the colonization of the producing species [29]. Class IIb bacteriocins consist of two peptides (<10 kDa), which act by increasing the porosity of the target cells’ membrane [30]. S. downii produces a class IIb bacteriocin lactobinA/cerein 7B that is thermostable and resistant to the action of proteinase K [31].
Using primers specific to this bacteriocin’s operon, the detected prevalence of S. downii in this study was ≤1%, both in the DS group and in the general population. This bacteriocin was identified in the two strains of S. downii deposited in the Spanish Type Culture Collection (Colección Española de Cultivos Tipo, CECT) and in the Swedish collection (Culture Collection University of Gothenburg; access numbers CECT:9732T and CCUG:73139T). This could represent a limitation of the study, given that the prevalence of S. downii could have been underestimated, if it is confirmed that not all strains of S. downii express the same bacteriocins or the same bacteriocin-related gene clusters, as occurs with S. dentisani [32].
The sequencing of the 16S rRNA gene has been the most widely used genetic marker by far in recent years for studying bacterial phylogeny and taxonomy, although it is not exempt from a number of limitations such as sequence similarity between different species of the Streptococcus genus [33]. Careful interpretation of the results of the distribution of other streptococci with S. mutans inhibitory activity such as S. dentisani is required. S. dentisani could be overestimated, given that it has been identified in most metagenomes of dental plaque stored in the Human Microbiome Project [9] and in all of the samples of saliva and dental plaque analyzed from various geographical locations worldwide [34]. To increase the reliability of the taxonomic assignation at the Streptococcus species level in the saliva microbiota, it has been suggested that matrix-assisted laser/desorption ionization time-of-flight mass spectrometry analysis is an accurate and consistent method [35]. The use of tools such as the web server BAGEL4 enables the (meta-) genomic analysis of bacterial DNA sequences to identify bacteriocins [36] and has already been incorporated among the methods for analyzing bacteriocin clusters of S. dentisani [32].

3.2. Prevalence of S. downii in Metagenomes of Supragingival Plaque of the Human Microbiome Project

Of the 127 selected metagenomes, only one obtained an ANIm with ≈95% homology (metagenome SRS013533), which had the highest nucleotide identity with S. downii. In the S. downii genome, we detected the presence of two open reading frames (ORFs) that coded class IIb lactobiocin A/cerein 7B bacteriocins and nine ORFs that coded accessory proteins to these bacteriocins (Table 1). When analyzing the presence of these genes in the 127 selected metagenomes, we detected 100% homology in metagenome SRS013533, along with high homology of the ORFs related to accessory proteins to this bacteriocin (Table S2). Although we obtained a high degree of homology of the genes related to bacteriocins in another four metagenomes, the ANIm value was <94% in all of them. This result allows us to conclude that the prevalence of S. downii in the metagenomes of supragingival plaque of the Human Microbiome Project was 0.7%, which agrees with the results using the PCR designed for the operon of bacteriocin (class IIb lactobin A/cerein 7B family).
Other potential methodological limitations are those derived from the metagenome-genome comparison and the small size of the detected sequences of the genes related to bacteriocins. The recommended cut-off point of 70% DNA-DNA hybridization (DDH) for species delineation corresponds to 95% ANI [27,37,38], which was what we detected in metagenome SRS013533. Although the ANI represents the percentage of identity of preserved genes between two strains, the threshold suggested in recent studies for the genome-genome comparison has been equally useful for the metagenome-genome comparison [39]. Although the size of the aligned sequence in the search for genes related to bacteriocins was small, it was close to the criterion proposed by other authors [40].

3.3. Clinical Results of Individuals with Down Syndrome and of the General Population

The results of the clinical intraoral examination are detailed in Table 2. Although this was not a primary objective of the study per se, it was essential for establishing a clinical-microbiological correlation in terms of the prevalence of caries and periodontal disease. This correlation obviously could not be established due to the low detected prevalence of S. downii.
Visible dental plaque was detected in 60.0% and 76.0% of the DS group and CG, respectively. For those younger than 30 years, the rates were 61.5% and 72.1%, respectively. Among those older than 30 years, 51.6% and 90.4% of the DS group and CG had dental plaque, respectively. The prevalence of caries was 40.5% and 51.0% among the DS group and CG, respectively. For those younger than 30 years, the rates were 39.0% and 53.1%, respectively. Among those older than 30 years, 48.3% and 42.8% of the DS group and CG had caries, respectively. Some 71.5% of the DS group and 66.0% of the CG had gingivitis. For those younger than 30 years, the rates were 68.0% and 67.1%, respectively. Among those older than 30 years, 90.3% of the DS group and 61.9% of the CG had gingivitis. The diagnostic criteria for periodontitis were met by 35.5% and 32.0% of the DS group and CG, respectively. For those younger than 15 years, periodontitis was detected in 14.5% of the DS group and in none of the CG. Among those younger than 30 years, the rates were 30.7% and 31.6%, respectively. Among those older than 30 years, 61.2% and 33.3% of the DS group and CG had periodontitis, respectively.
Although it has been speculated that the combination of poor control over dental plaque and a deficient immune system might promote the development of caries in individuals with DS, the present series recorded a lower prevalence of caries in the DS group than in the CG, confirming the results of previous studies [12,13,14,15]. It has been argued that this finding could be due to delayed tooth eruption, microdontia, tooth agenesis and the presence of diastemas [41]. The bacterial flora plays a fundamental role in the etiopathogenesis of caries, and it has been shown that children and adolescents with DS have a lower density of S. mutans in saliva samples than nonsyndromic controls [42,43]. Additionally, the molecular typing of S. mutans using arbitrarily primed PCR revealed that the strains that colonize the tooth surface have different, presumably less cariogenic profiles in DS than in non-syndromic controls [44].
In the present series, gingivitis and periodontitis were more prevalent in the DS group than in the CG, confirming that gingivitis and periodontal disease occur more frequently in individuals with DS, have an earlier onset and are more severe than in the general population [45,46,47]. It has been suggested that the development of periodontitis in these patients is due to a specific subgingival microbiota [48], along with the host’s abnormal, syndrome-inherent immune response [49].
Recent studies that applied next-generation sequencing have shown substantial differences in the composition of the oral microbiome between patients with DS and non-syndromic individuals, with a significantly lower diversity of species (i.e., alpha diversity) and an increased presence of periodontal pathogens in DS [50]. In individuals with DS, the microbiome differs significantly between those who have an oral condition (e.g., periodontal disease) and those who do not [51]. The influence of bacteria with anticaries and antiperiodontitis potential such as S. downii on the composition and homeostasis of the oral microbiome in individuals with DS is still unknown.
It has been suggested that, for individuals with DS and periodontal disease, non-surgical periodontal therapy is effective in terms of clinical parameters; unlike with euploid individuals, however, this therapy does not cause a significant reduction in red-complex bacteria levels in deep periodontal pockets [52]. Accordingly, these authors suggested that, in individuals with DS, the results of mechanical periodontal treatment might be improved if adjuvants are used to reduce periodontal pathogen counts [52]. The fight against antibiotic resistance has become a priority health action, in which infection prevention and a more restrictive antibiotic policy are essential [53]. Accordingly, there has been growing interest in a number of alternative strategies to antibiotics in the dental setting, strategies that do not share the adverse effects of antibiotics, such as antimicrobial photodynamic therapy [54] and the use of probiotics to re-establish oral homeostasis [55]. The interest in detecting S. downii lies in its antibacterial activity against a number of cariogenic species and certain periodontal pathogens [17,18], which makes S. downii a potential probiotic.

4. Conclusions

Applying a specific PCR for the bacteriocin operon (class IIb lactobin A/cerein 7B family) of S. downii, the detection rate of this novel streptococcal species in the supragingival dental plaque was ≤1%, both in Down syndrome and in the general population. A clinical-microbiological correlation could therefore not be established.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms10061098/s1, Table S1. Quantification cycle (Cq) value and genome equivalent of S. downii (GE)/μL for the target (bacteriocin) and control genes (16S rRNA) of supragingival dental plaque samples seeded with S. downii at 3000 CFU/mL. Table S2. Results of the analysis using Blast reciprocal best hits (BRBH) of the genes related to bacteriocins present in S. downii in the metagenome SRS013533.

Author Contributions

Conceptualization, L.M.-L., M.Á.-F., E.G.-M. and P.D.-D.; Methodology, E.G.-M., L.M.-L., I.V.-A. and M.Á.-F.; Investigation, E.G.-M., L.M.-L., I.V.-A., M.D.-F. and J.L.-P.; Writing-original draft preparation, E.G.-M., L.M.-L., M.D.-F. and J.L.-P.; Writing-review and editing, L.M.-L., M.Á.-F., J.L.-P. and P.D.-D.; Supervision, M.Á.-F. and P.D.-D.; Project administration, M.D.-F. and J.L.-P.; Funding acquisition, L.M.-L., M.Á.-F., J.L.-P. and P.D.-D. All authors have read and agreed to the published version of the manuscript.

Funding

This research was co-funded by the Xunta de Galicia under the Ignicia Programme, Axencia Galega de Innovación, GAIN (12/08/2016; GRANT_NUMBER: IN855A).

Institutional Review Board Statement

Research Ethics Committee of Santiago-Lugo, Spain (Registration code: 2018/510).

Informed Consent Statement

All participants (or their legal representatives) signed an informed consent document.

Data Availability Statement

Data available upon request due to restrictions. The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy issues.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858, published correction appears in Lancet 2019, 393, e44. [Google Scholar] [CrossRef] [Green Version]
  2. Mira, A.; Simon-Soro, A.; Curtis, M.A. Role of microbial communities in the pathogenesis of periodontal diseases and caries. J. Clin. Periodontol. 2017, 44, S23–S38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Gross, E.L.; Beall, C.J.; Kutsch, S.R.; Firestone, N.D.; Leys, E.J.; Griffen, A.L. Beyond Streptococcus mutans: Dental caries onset linked to multiple species by 16S rRNA community analysis. PLoS ONE 2012, 7, e47722. [Google Scholar] [CrossRef] [PubMed]
  4. Tong, H.; Chen, W.; Merritt, J.; Qi, F.; Shi, W.; Dong, X. Streptococcus oligofermentans inhibits Streptococcus mutans through conversion of lactic acid into inhibitory H2O2: A possible counteroffensive strategy for interspecies competition. Mol. Microbiol. 2007, 63, 872–880. [Google Scholar] [CrossRef]
  5. Huang, X.; Palmer, S.R.; Ahn, S.J.; Richards, V.P.; Williams, M.L.; Nascimento, M.M.; Burne, R.A. A Highly Arginolytic Streptococcus Species That Potently Antagonizes Streptococcus mutans. Appl. Environ. Microbiol. 2016, 82, 2187–2201. [Google Scholar] [CrossRef] [Green Version]
  6. Huang, X.; Browngardt, C.M.; Jiang, M.; Ahn, S.J.; Burne, R.A.; Nascimento, M.M. Diversity in antagonistic interactions between commensal oral streptococci and Streptococcus mutans. Caries Res. 2018, 52, 88–101. [Google Scholar] [CrossRef]
  7. Wescombe, P.A.; Heng, N.C.; Burton, J.P.; Tagg, J.R. Something Old and Something New: An Update on the Amazing Repertoire of Bacteriocins Produced by Streptococcus salivarius. Probiotics Antimicrob. Proteins 2010, 2, 37–45. [Google Scholar] [CrossRef]
  8. Camelo-Castillo, A.; Benítez-Páez, A.; Belda-Ferré, P.; Cabrera-Rubio, R.; Mira, A. Streptococcus dentisani sp. nov., a novel member of the Mitis group. Int. J. Syst. Appl. Microbiol. 2014, 64, 60–65. [Google Scholar] [CrossRef]
  9. López-López, A.; Camelo-Castillo, A.; Ferrer, M.D.; Simon-Soro, Á.; Mira, A. Health-Associated Niche Inhabitants as Oral Probiotics: The Case of Streptococcus dentisani. Front. Microbiol. 2017, 8, 379. [Google Scholar] [CrossRef]
  10. Bull, M.J. Down Syndrome. N. Engl. J. Med. 2020, 382, 2344–2352. [Google Scholar] [CrossRef]
  11. Mubayrik, A.B. The Dental Needs and Treatment of Patients with Down Syndrome. Dent. Clin. N. Am. 2016, 60, 613–626. [Google Scholar] [CrossRef] [PubMed]
  12. Deps, T.D.; Angelo, G.L.; Martins, C.C.; Paiva, S.M.; Pordeus, I.A.; Borges-Oliveira, A.C. Association between Dental Caries and Down Syndrome: A Systematic Review and Meta-Analysis. PLoS ONE 2015, 10, e0127484. [Google Scholar] [CrossRef] [PubMed]
  13. Moreira, M.J.; Schwertner, C.; Jardim, J.J.; Hashizume, L.N. Dental caries in individuals with Down syndrome: A systematic review. Int. J. Paediatr. Dent. 2016, 26, 3–12. [Google Scholar] [CrossRef] [PubMed]
  14. Robertson, M.D.; Schwendicke, F.; de Araujo, M.P.; Radford, J.R.; Harris, J.C.; McGregor, S.; Innes, N.P.T. Dental caries experience, care index and restorative index in children with learning disabilities and children without learning disabilities; a systematic review and meta-analysis. BMC Oral Health 2019, 19, 146. [Google Scholar] [CrossRef] [Green Version]
  15. Silva, M.C.P.M.D.; Lyra, M.C.A.; Almeida, H.C.R.; Alencar Filho, A.V.; Heimer, M.V.; Rosenblatt, A. Caries experience in children and adolescents with Down Syndrome: A systematic review and meta-analysis. Arch. Oral Biol. 2020, 115, 104715. [Google Scholar] [CrossRef]
  16. Bhoopathi, V.; Tellez, M. Limited quality evidence suggests children and adolescents with down syndrome have lower prevalence of dental caries compared to non-syndromic children. J. Evid. Based Dent. Pract. 2021, 21, 101571. [Google Scholar] [CrossRef]
  17. Martínez-Lamas, L.; Limeres-Posse, J.; Diz-Dios, P.; Álvarez-Fernández, M. Streptococcus downii sp. nov., isolated from the oral cavity of a teenager with Down syndrome. Int. J. Syst. Evol. Microbiol. 2020, 70, 4098–4104. [Google Scholar] [CrossRef]
  18. Cuenca, M.; Sánchez, M.C.; Diz, P.; Martínez-Lamas, L.; Álvarez, M.; Limeres, J.; Sanz, M.; Herrera, D. In Vitro Anti-Biofilm and Antibacterial Properties of Streptococcus downii sp. nov. Microorganisms 2021, 9, 450. [Google Scholar] [CrossRef]
  19. Ramfjord, S.P. Indices for Prevalence and Incidence of Periodontal Disease. J. Periodontol. 1959, 30, 51–59. [Google Scholar] [CrossRef] [Green Version]
  20. O’Leary, T.J.; Drake, R.B.; Naylor, J.E. The plaque control record. J. Periodontol. 1972, 43, 38. [Google Scholar] [CrossRef]
  21. Pitts, N.B. ‘ICDAS’—An international system for caries detection and assessment being developed to facilitate caries epidemiology, research and appropriate clinical management. Community Dent. Health 2004, 21, 193–198. [Google Scholar]
  22. Chapple, I.L.C.; Mealey, B.L.; Van Dyke, T.E.; Bartold, P.M.; Dommisch, H.; Eickholz, P.; Geisinger, M.L.; Genco, R.J.; Glogauer, M.; Goldstein, M.; et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Clin. Periodontol. 2018, 45, S68–S77. [Google Scholar] [CrossRef] [PubMed]
  23. Tonetti, M.S.; Greenwell, H.; Kornman, K.S. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J. Periodontol. 2018, 89, S159–S172, Erratum in: J. Periodontol. 2018, 89, 1475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. NIH Human Microbiome Project—Home [WWW Document], n.d. URL. Available online: https://www.hmpdacc.org/ (accessed on 5 January 2022).
  25. Kurtz, S.; Phillippy, A.; Delcher, A.L.; Smoot, M.; Shumway, M.; Antonescu, C.; Salzberg, S.L. Versatile and open software for comparing large genomes. Genome Biol. 2004, 5, R12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Pritchard, L.; Glover, R.H.; Humphris, S.; Elphinstone, J.G.; Toth, I.K. Genomics and taxonomy in diagnostics for food security: Soft-rotting enterobacterial plant pathogens. Anal. Methods 2016, 8, 12–24. [Google Scholar] [CrossRef]
  27. Richter, M.; Rosselló-Móra, R. Shifting the genomic gold standard for the prokaryotic species definition. Proc. Natl. Acad. Sci. USA 2009, 106, 19126–19131. [Google Scholar] [CrossRef] [Green Version]
  28. Gabaldón, T. Comparative genomics-based prediction of protein function. Methods Mol. Biol. 2008, 439, 387–401. [Google Scholar] [CrossRef]
  29. Kommineni, S.; Bretl, D.J.; Lam, V.; Chakraborty, R.; Hayward, M.; Simpson, P.; Cao, Y.; Bousounis, P.; Kristich, C.J.; Salzman, N.H. Bacteriocin Production Augments Niche Competition by Enterococci in the Mammalian Gastrointestinal Tract. Nature 2015, 526, 719–722. [Google Scholar] [CrossRef] [Green Version]
  30. Nissen-Meyer, J.; Rogne, P.; Oppegård, C.; Haugen, H.S.; Kristiansen, P.E. Structure-function relationships of the non-lanthionine-containing peptide (class II) bacteriocins produced by gram-positive bacteria. Curr. Pharm. Biotechnol. 2009, 10, 19–37. [Google Scholar] [CrossRef]
  31. Pentoscope. WO2018096118—Antimicrobial Strain. Available online: https://patentscope.wipo.int/search/es/detail.jsf?docId=WO2018096118&_cid=P21-KYAEJ2-26113-1 (accessed on 1 December 2021).
  32. Conrads, G.; Westenberger, J.; Lürkens, M.; Abdelbary, M.M.H. Isolation and Bacteriocin-Related Typing of Streptococcus dentisani. Front. Cell. Infect. Microbiol. 2019, 9, 110. [Google Scholar] [CrossRef]
  33. Janda, J.M.; Abbott, S.L. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: Pluses, perils, and pitfalls. J. Clin. Microbiol. 2007, 45, 2761–2764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. López-Santacruz, H.D.; López-López, A.; Revilla-Guarinos, A.; Camelo-Castillo, A.; Esparza-Villalpando, V.; Mira, A.; Aranda-Romo, S. Streptococcus dentisani is a common inhabitant of the oral microbiota worldwide and is found at higher levels in caries-free individuals. Int. Microbiol. 2021, 24, 619–629. [Google Scholar] [CrossRef] [PubMed]
  35. Złoch, M.; Rodzik, A.; Pauter, K.; Szultka-Młyńska, M.; Rogowska, A.; Kupczyk, W.; Pomastowski, P.; Buszewski, B. Problems with identifying and distinguishing salivary streptococci: A multi-instrumental approach. Future Microbiol. 2020, 15, 1157–1171. [Google Scholar] [CrossRef] [PubMed]
  36. van Heel, A.J.; de Jong, A.; Song, C.; Viel, J.H.; Kok, J.; Kuipers, O.P. BAGEL4: A user-friendly web server to thoroughly mine RiPPs and bacteriocins. Nucleic Acids Res. 2018, 46, W278–W281. [Google Scholar] [CrossRef]
  37. Konstantinidis, K.T.; Tiedje, J.M.; 2005. Genomic insights that advance the species definition for prokaryotes. Proc. Natl. Acad. Sci. USA 2005, 102, 2567–2572. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Goris, J.; Konstantinidis, K.T.; Klappenbach, J.A.; Coenye, T.; Vandamme, P.; Tiedje, J.M. DNA-DNA hybridization values and their relationship to whole-genome sequence similarities. Int. J. Syst. Evol. Microbiol. 2007, 57, 81–91. [Google Scholar] [CrossRef] [Green Version]
  39. Olm, M.R.; Crits-Christoph, A.; Diamond, S.; Lavy, A.; Matheus Carnevali, P.B.; Banfield, J.F. Consistent Metagenome-Derived Metrics Verify and Delineate Bacterial Species Boundaries. mSystems 2020, 5, e00731-19. [Google Scholar] [CrossRef] [Green Version]
  40. Schubert, M.; Ginolhac, A.; Lindgreen, S.; Thompson, J.F.; Al-Rasheid, K.A.S.; Willerslev, E.; Krogh, A.; Orlando, L. Improving ancient DNA read mapping against modern reference genomes. BMC Genom. 2012, 13, 178. [Google Scholar] [CrossRef] [Green Version]
  41. Vigild, M. Dental caries experience among children with down’s syndrome. J. Ment. Defic. Res. 1986, 30, 271–276. [Google Scholar]
  42. Areias, C.; Sampaio-Maia, B.; Pereira Mde, L.; Azevedo, A.; Melo, P.; Andrade, C.; Scully, C. Reduced salivary flow and colonization by mutans streptococci in children with Down syndrome. Clinics 2012, 67, 1007–1011. [Google Scholar] [CrossRef]
  43. Scalioni, F.; Carrada, C.; Machado, F.; Devito, K.; Ribeiro, L.C.; Cesar, D.; Ribeiro, R. Salivary density of Streptococcus mutans and Streptococcus sobrinus and dental caries in children and adolescents with Down syndrome. J. Appl. Oral Sci. 2017, 25, 250–257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Cogulu, D.; Sabah, E.; Uzel, A.; Ozkinay, F. Genotyping of Streptococcus mutans by using arbitrarily primed polymerase chain reaction in children with Down Syndrome. Arch. Oral Biol. 2006, 51, 177–182. [Google Scholar] [CrossRef] [PubMed]
  45. Morinushi, T.; Lopatin, D.E.; Van Poperin, N. The relationship between gingivitis and the serum antibodies to the microbiota associated with periodontal disease in children with Down's syndrome. J. Periodontol. 1997, 68, 626–631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Lopez-Pérez, R.; Borges-Yáñez, S.A.; Jiménez-García, G.; Maupomé, G. Oral hygiene, gingivitis, and periodontitis in persons with Down syndrome. Spec. Care Dent. 2002, 22, 214–220. [Google Scholar] [CrossRef]
  47. Sakellari, D.; Arapostathis, K.N.; Konstantinidis, A. Periodontal conditions and subgingival microflora in Down syndrome patients. A case-control study. J. Clin. Periodontol. 2005, 32, 684–690. [Google Scholar] [CrossRef]
  48. Martinez-Martinez, R.E.; Loyola-Rodriguez, J.P.; Bonilla-Garro, S.E.; Patiño-Marin, N.; Haubek, D.; Amano, A.; Poulsen, K. Characterization of periodontal biofilm in Down syndrome patients: A comparative study. J. Clin. Pediatr. Dent. 2013, 37, 289–295. [Google Scholar] [CrossRef]
  49. Khocht, A.; Albandar, J.M. Aggressive forms of periodontitis secondary to systemic disorders. Periodontol. 2000 2014, 65, 134–148. [Google Scholar] [CrossRef]
  50. Willis, J.R.; Iraola-Guzmán, S.; Saus, E.; Ksiezopolska, E.; Cozzuto, L.; Bejarano, L.A.; Andreu-Somavilla, N.; Alloza-Trabado, M.; Puig-Sola, A.; Blanco, A.; et al. Oral microbiome in Down syndrome and its implications on oral health. J. Oral Microbiol. 2020, 13, 1865690. [Google Scholar] [CrossRef]
  51. Nóvoa, L.; Sánchez, M.D.C.; Blanco, J.; Limeres, J.; Cuenca, M.; Marín, M.J.; Sanz, M.; Herrera, D.; Diz, P. The Subgingival Microbiome in Patients with Down Syndrome and Periodontitis. J. Clin. Med. 2020, 9, 2482. [Google Scholar] [CrossRef]
  52. Tanaka, M.H.; Rodrigues, T.O.; Finoti, L.S.; Teixeira, S.R.; Mayer, M.P.; Scarel-Caminaga, R.M.; Giro, E.M. The effect of conventional mechanical periodontal treatment on red complex microorganisms and clinical parameters in Down syndrome periodontitis patients: A pilot study. Eur. J. Clin. Microbiol. Infect Dis. 2015, 34, 601–608. [Google Scholar] [CrossRef]
  53. CDC. Antibiotic Resistance Threats in the United States, 2019; U.S. Department of Health and Human Services, CDC: Atlanta, GA, USA, 2019. [Google Scholar]
  54. Chiniforush, N.; Pourhajibagher, M.; Parker, S.; Benedicenti, S.; Bahador, A.; Sălăgean, T.; Bordea, I.R. The Effect of Antimicrobial Photodynamic Therapy Using Chlorophyllin–Phycocyanin Mixture on Enterococcus faecalis: The Influence of Different Light Sources. Appl. Sci. 2020, 10, 4290. [Google Scholar] [CrossRef]
  55. Hoare, A.; Marsh, P.D.; Diaz, P.I. Ecological Therapeutic Opportunities for Oral Diseases. Microbiol. Spectr. 2017, 5. [Google Scholar] [CrossRef] [PubMed]
Figure 1. DNA sequence of S. downii indicating the position of the primers (marked in green) and the two open reading frames of the encoded bacteriocins in this fragment (marked in blue and yellow).
Figure 1. DNA sequence of S. downii indicating the position of the primers (marked in green) and the two open reading frames of the encoded bacteriocins in this fragment (marked in blue and yellow).
Microorganisms 10 01098 g001
Figure 2. (a) Specificity assay using primers specific for the bacteriocin operon of Streptococcus downii (St.1: S. mitis; St.2: S. salivarius; St.3: S. dentisani 8313; St.4: S. dentisani 8312; St.5: S. mutans; St.6: S. sobrinus; St.7: S. sanguinis DSTIZ 20567; St.8: S. downii). (b) Sensitivity assay using primers specific for the bacteriocin operon of Streptococcus downii (St.1: 460,000 copies, 1 ng of bacterial DNA; St.2: 92,000 copies, 2 × 10−1 ng; St.3: 18,400 copies, 4 × 10−2 ng; St.4: 3680 copies, 8 × 10−3 ng; St.5: 736 copies, 1.6 × 10−3 ng; St.6: 147.2 copies, 3.2 × 10−4 ng; St.7: 29.44 copies, 6.24 × 10−5 ng; St.8: 5.888 copies, 1.28 × 10−5; St.9: 1.1776 copies, 2.56 × 10−6; St.10: the DNA of S.downii was not included).
Figure 2. (a) Specificity assay using primers specific for the bacteriocin operon of Streptococcus downii (St.1: S. mitis; St.2: S. salivarius; St.3: S. dentisani 8313; St.4: S. dentisani 8312; St.5: S. mutans; St.6: S. sobrinus; St.7: S. sanguinis DSTIZ 20567; St.8: S. downii). (b) Sensitivity assay using primers specific for the bacteriocin operon of Streptococcus downii (St.1: 460,000 copies, 1 ng of bacterial DNA; St.2: 92,000 copies, 2 × 10−1 ng; St.3: 18,400 copies, 4 × 10−2 ng; St.4: 3680 copies, 8 × 10−3 ng; St.5: 736 copies, 1.6 × 10−3 ng; St.6: 147.2 copies, 3.2 × 10−4 ng; St.7: 29.44 copies, 6.24 × 10−5 ng; St.8: 5.888 copies, 1.28 × 10−5; St.9: 1.1776 copies, 2.56 × 10−6; St.10: the DNA of S.downii was not included).
Microorganisms 10 01098 g002
Table 1. Main genes related to bacteriocins present in the genome of S. downii.
Table 1. Main genes related to bacteriocins present in the genome of S. downii.
ORF idContigORF StartORF EndStrandDescription
gene_00016contig_11343913582+Class IIb bacteriocin, lactobin A/cerein 7B family
gene_00017contig_11359813756+Bacteriocin-type signal sequence domain-containing protein
gene_00019contig_11415314308+Class IIb bacteriocin, lactobin A/cerein 7B family protein
gene_00020contig_11434714559+Bacteriocin immunity protein
gene_00022contig_11485315062+Bacteriocin immunity protein
gene_00024contig_11574517898+Peptide cleavage/export ABC transporter
gene_00402contig_65832858624Bacteriocin immunity protein
gene_00657contig_6307826309934Bacteriocin-associated integral membrane family protein
gene_00673contig_6326623326919Bacteriocin immunity protein
gene_01111contig_8277351277698Thiol reductase thioredoxin
gene_01818contig_9605338606096+Bacteriocin ABC transporter ATP-binding protein
Table 2. (a) Clinical Characteristics of the Study Group with Down syndrome. (b) Clinical Characteristics of the non-syndromic Control Group.
Table 2. (a) Clinical Characteristics of the Study Group with Down syndrome. (b) Clinical Characteristics of the non-syndromic Control Group.
(a)
Age
(Years)
Dental Plaque
(n)
Caries
(n)
Gingivitis
(n)
Periodontal
Disease (n)
Total
(n)
0–5120013
6–101279220
11–1513215622
16–202819321242
21–252514261334
26–302522331938
31–357613914
36–40768310
41–4522444
46–5000111
51–5501222
56–6000000
Total1208114371200
(b)
Age
(Years)
Dental Plaque
(n)
Caries
(n)
Gingivitis
(n)
Periodontal
Disease (n)
Total
(n)
0–511103
6–10978011
11–1514914016
16–201099910
21–251515151528
26–30816111
31–3521212
36–401267214
41–4531333
46–5011111
51–5500000
56–6010001
Total76516632100
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

García-Mato, E.; Martínez-Lamas, L.; Álvarez-Fernández, M.; Varela-Aneiros, I.; Diniz-Freitas, M.; Limeres-Posse, J.; Diz-Dios, P. Molecular Detection of Streptococcus downii sp. nov. from Dental Plaque Samples from Patients with Down Syndrome and Non-Syndromic Individuals. Microorganisms 2022, 10, 1098. https://doi.org/10.3390/microorganisms10061098

AMA Style

García-Mato E, Martínez-Lamas L, Álvarez-Fernández M, Varela-Aneiros I, Diniz-Freitas M, Limeres-Posse J, Diz-Dios P. Molecular Detection of Streptococcus downii sp. nov. from Dental Plaque Samples from Patients with Down Syndrome and Non-Syndromic Individuals. Microorganisms. 2022; 10(6):1098. https://doi.org/10.3390/microorganisms10061098

Chicago/Turabian Style

García-Mato, Eliane, Lucía Martínez-Lamas, Maximiliano Álvarez-Fernández, Iván Varela-Aneiros, Marcio Diniz-Freitas, Jacobo Limeres-Posse, and Pedro Diz-Dios. 2022. "Molecular Detection of Streptococcus downii sp. nov. from Dental Plaque Samples from Patients with Down Syndrome and Non-Syndromic Individuals" Microorganisms 10, no. 6: 1098. https://doi.org/10.3390/microorganisms10061098

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop